吉峯科技(300022.SZ)擬定增募資不超3.35億元 由成經建發認購
格隆匯5月7日丨吉峯科技(300022.SZ)披露非公開發行A股股票預案,擬非公開發行股票的數量為1億股,佔此次非公開發行前公司總股本的26.30%;非公開發行的發行價格為3.35元/股。
募集資金總額為3.35億元,在扣除發行費用後將全部用於償還有息負債。
發行對象為成都經濟技術開發區建設發展有限公司(“成經建發”)。發行對象以現金全額認購此次發行的股票。
截至預案公告日,王新明及其關聯人(王紅豔、山南神宇、王海名)合計持有上市公司9619.75萬股股份,佔公司總股本的25.30%;王新明、王紅豔夫婦為公司的控股股東和實際控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.